Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Marker Therapeutics develops T cell-based immunotherapies to treat blood cancers and solid tumors.
Marker Therapeutics is a small clinical-stage biotech company working on a different way to fight cancer. Instead of making a drug in a factory and injecting it, Marker takes immune cells called T cells — the body's own soldiers — and trains them to recognize and attack cancer cells. The company's approach is to give patients a mixture of these trained T cells rather than a single engineered cell type, with the goal of mounting a broader and more durable attack on tumors, particularly blood cancers like leukemia and lymphoma.
Here's the basic idea from first principles. A cancer cell is a corrupted version of your own cell, so the immune system often struggles to tell it apart from healthy tissue. Marker's job is to take a patient's or donor's T cells, teach them to spot the markers that scream "cancer," grow them into an army in the lab, and then infuse them back. The promise is that these living cells can hunt down cancer and stick around as a kind of standing defense, which is a very different product from a pill you take every day. Like most clinical-stage biotechs, Marker does not yet sell anything. Its money comes from investors and partners, and it burns cash on laboratory work and human trials. The company was formerly known as TapImmune, and today it is a very small player in the crowded field of cell therapy, competing against far larger and better-funded rivals. That means the whole story hinges on whether its clinical trials produce strong enough results to attract a partner or the capital to keep going.
For a company like this, the risks are blunt: trials fail, cash runs out, and promising science often never becomes an approved medicine. Marker's future depends on convincing data from its studies, which in turn could draw partnerships or funding. Until then, it is a bet on an idea — using a mix of trained immune cells to outsmart cancer — rather than a business with steady revenue.
Saved answer · last researched 15 Nov 2026